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OBJECTIVE — Abnormal cellular cholesterol handling in islets may contribute to -cell
dysfunction in type 2 diabetes. -Cell deﬁciency for the ATP binding cassette transporter A1
(ABCA1), which mediates the efﬂux of cellular cholesterol, leads to altered intracellular choles-
terol homeostasis and impaired insulin secretion in mice. We aimed to assess the impact of
ABCA1 dysfunction on glucose homeostasis in humans.
RESEARCH DESIGN AND METHODS — In heterozygous carriers of disruptive mu-
tations in ABCA1 and family-based noncarriers of similar age, sex, and BMI, we performed oral
glucose tolerance tests (OGTTs) (n  15 vs. 14) and hyperglycemic clamps (n  8 vs. 8).
RESULTS — HDL cholesterol levels in carriers were less than half those in noncarriers, but
LDL cholesterol levels did not differ. Although fasting plasma glucose was similar between
groups, glucose curves after an OGTT were mildly higher in carriers than in noncarriers. During
hyperglycemic clamps, carriers demonstrated lower ﬁrst-phase insulin secretion than noncarri-
ers but no difference in insulin sensitivity. The disposition index (a measure of -cell function
adjustedforinsulinsensitivity)ofthecarrierswassigniﬁcantlyreducedinABCA1heterozygotes.
CONCLUSIONS — Carriers of loss-of-function mutations in ABCA1 show impaired insulin
secretion without insulin resistance. Our data provide evidence that ABCA1 is important for
normal -cell function in humans.
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T
he reasons for -cell dysfunction in
type2diabetesareincompletelyun-
derstood. One hypothesis suggests
that the accumulation of toxic lipid leads
to the loss of insulin secretion character-
isticofthisdisorder(1).Althoughtherole
of free fatty acids and triglycerides has
been extensively studied (2), much less is
knownabouttheroleofcholesterolinthis
process. The ATP-binding cassette trans-
porter, subfamily A, member 1 (ABCA1)
regulates the rate-limiting step in choles-
terol transport out of cells and is thus a
candidate molecule for inﬂuencing cho-
lesterol metabolism in -cells.
In humans, homozygosity for natu-
rally occurring loss-of-function muta-
tions in ABCA1 leads to Tangier disease,
an extremely rare disorder characterized
by near absence of HDL cholesterol in
plasma as well as a 30–40% reduction in
LDL cholesterol, increased risk of coro-
nary artery disease (CAD), and accumu-
lation of cholesterol in tissues (3).
Approximately 100 cases of Tangier dis-
ease have been reported worldwide. Het-
erozygous carriers of loss-of-function
mutations in ABCA1, generally ascer-
tained from Tangier disease pedigrees,
also exhibit decreased HDL cholesterol
levels and accelerated atherogenesis due
to impaired removal of cholesterol from
lipid-laden macrophages in the presence
of relatively normal levels of total plasma
cholesterol (4).
Targeted deletion of -cell Abca1 in
mice results in accumulation of choles-
terolinislets,reducedglucose-stimulated
insulin secretion (GSIS), and impaired
glucose tolerance (5). In addition, the
common ABCA1 polymorphism R230C
was shown to be associated with a four-
foldincreaseintheoccurrenceofdiabetes
in a Mexican population (6). These novel
ﬁndings imply an important role for
ABCA1 in maintaining glucose-mediated
insulin secretion.
Interestingly,micelackingAbca1spe-
ciﬁcally in -cells have a more severe im-
pairment in -cell function compared
with mice lacking Abca1 globally, possi-
bly because of the higher levels of total
plasma cholesterol in mice with -cell–
speciﬁc deletion of Abca1. This ﬁnding
suggeststhatthedegreeof-celldysfunc-
tion caused by ABCA1 deﬁciency may re-
late to the level of plasma cholesterol to
which the islets are exposed. To assess
whetherdeﬁciencyofABCA1functionin-
ﬂuences -cell function in humans, we
therefore chose to study carriers of het-
erozygous ABCA1 mutations, with severe
reductions in ABCA1 function but rela-
tivelynormaltotalplasmacholesterollev-
els. We performed oral glucose tolerance
tests (OGTTs) and hyperglycemic clamps
inABCA1heterozygotesandfamily-based
control subjects. Our data indicate that
ABCA1 plays a signiﬁcant role in insulin
secretion and -cell function in humans.
RESEARCH DESIGN AND
METHODS— During the past de-
cade, we have used our lipid clinic net-
work and contacts with general
practitioners in the Netherlands to collect
plasma and DNA from individuals with
familial hypoalphalipoproteinemia, with
theintentofidentifyinggenesthatcontrol
HDLcholesterollevels.Wecontactedhet-
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function mutations in ABCA1 and
unaffected (family) control subjects of
similar age, sex, and BMI and asked them
to participate. Written informed consent
wasobtainedafterexplanationofthepur-
pose, nature, and potential risks of the
study. All subjects who gave informed
consent were included in the study and
theﬁnalanalysis.Thestudywasapproved
by the institutional review board of the
Academic Medical Center of the Univer-
sity of Amsterdam.
Genotyping
For mutation detection, genomic DNA
was prepared from 10 ml of whole blood
onanAutopureLSapparatusaccordingto
the manufacturer’s protocol (Gentra Sys-
tems,Minneapolis,MN).Forwardandre-
verse PCR primers, ﬂanking each exon,
weredesignedwithPrimer3(http://frodo.
wi.mit.edu). PCR ampliﬁcation was per-
formed with 50 ng genomic DNA in a
25-l reaction volume containing 1
Taq DNA polymerase buffer (Qiagen,
Hilden, Germany), 50 mol/l concentra-
tions of each dNTP, 0.4 mol/l concen-
trations of each primer, and 1 unit of Taq
DNA polymerase. The thermal cycling
conditions were as follows: 96°C for 5
min,then35cyclesof30sat96°C,30sat
60°C,and30sat72°CinaPCRapparatus
(T3 Biocycler; Biometra, Go ¨ttingen, Ger-
many). The sequence reactions were
performed using ﬂuorescently labeled
dideoxychainterminationswithaBigDye
terminator ABI Prismkit (Applied Biosys-
tems, Foster City, CA) according to the
manufacturer’s protocol and analyzed on
an automated DNA sequencer (model
370; Applied Biosystems). Sequences
were analyzed with the Sequencher pack-
age (Gene Codes, Ann Arbor, MI). Sub-
jects included in the present study were
heterozygous carriers of the following ex-
tremely rare ABCA1 mutations: C1477R,
M1091T, and R587W (4,7–10) and
L996P and Q978X (C. Candini et al.,
manuscriptinpreparation).Noneofthese
mutations were detected in 200 control
chromosomes. C1477R has been re-
ported in nine heterozygous individuals,
M1091T in four individuals, and R587W
in seven individuals (11).
OGTT
Subjects were asked to discontinue any
lipid-loweringmedication3weeksbefore
the study, except for those with a history
ofCAD.Onthemorningofthestudyday,
fasting plasma glucose and insulin were
determined after venous sampling of 4.5
ml of blood. Subsequently, subjects were
askedtoingest75gglucose,administered
as a 375-ml solution of 20% glucose in
water. At t  30, 60, 90, and 120 min
another 4.5-ml blood sample was ob-
tained for repetitive assessment of blood
glucose and insulin.
Hyperglycemic clamp
Weperformedhyperglycemicclampsina
subset of participants, on a separate day,
within 6 months of the OGTT. Subjects
were instructed to maintain their usual
diet preceding the study and to discon-
tinue any lipid-lowering medication 3
weeks before the study visit (unless there
wasahistoryofCAD).Onthestudydayat
9:00 A.M., an antecubital vein was cannu-
lated for blood sampling. Blood glucose
was measured using a bedside calibrated
glucose sensor (YSI 2300 STAT S; YSI,
Yellow Springs, OH). The antecubital
vein of the contralateral arm was cannu-
lated for infusions of 20% glucose and ar-
ginine hydrochloride (50 ml of 100 mg/
ml). First-phase insulin secretion was
determined using an intravenous glucose
bolus. On the basis of the fasting baseline
plasma glucose level and the subject’s
body weight, a 20% glucose bolus was
givenover1min,withtheaimofreaching
a plasma glucose level of 13 mmol/l
([weight/70  10  plasma glucose] ml
of a 20% glucose solution). Blood glucose
levels were kept at 13 mmol/l by contin-
uous glucose infusion. Pump settings
(glucose infusion rate) were adapted on
the basis of measured blood glucose lev-
els. Blood was collected at t  0, 2.5, 5,
7.5,10,and15minforthedetermination
of glucose, insulin, C-peptide, and gluca-
gon. Subsequently, blood was sampled
every 5 min for glucose determination. At
t  90, 100, 110, 120, 125, 130, 135,
140, 145, and 150 min blood was sam-
pledforhormonedetermination.Anargi-
ninebolus(5g)wasgivenatt120min.
Volunteers remained fasting until the end
of the study. Glucose administration was
then tapered over 30 min, and volunteers
were offered a carbohydrate-rich meal.
Plasma measurements
Total,HDL,andLDLcholesterolandtrig-
lycerides were determined in fasted
plasma using standard laboratory proce-
dures within 1 h after sampling. HDL
cholesterolwasdeterminedbyahomoge-
neous enzymatic colorimetric assay, us-
ing polyethylene glycol–modiﬁed
cholesterol esterase and oxidase (Roche,
Basel, Switzerland). A1C was determined
by high-performance liquid chromatog-
raphy. Insulin was determined on an Im-
mulite2000system(DiagnosticProducts,
Los Angeles, CA), using a chemilumines-
cent immunometric assay with an intra-
assay variation of 1.6–5.8%, interassay
variation of 3.6–6.4%, and detection
limit of 15 pmol/l. Glucagon was deter-
mined with the Linco
125I radioimmuno-
assay (RIA) (Linco Research, St. Charles,
MO) with an intra-assay variation of 3.4–
5.8%, interassay variation of 9.8–10.9%,
and detection limit of 15 ng/l. C-peptide
was measured by RIA (RIA-coat C-
peptide; Byk-Sangtec Diagnostica, Diet-
zenbach, Germany) with an intra-assay
variation of 6.3–9.2%, interassay varia-
tion of 7.0–14.2%, and detection limit of
50 pmol/l.
Calculations
Homeostasis model assessment (HOMA)
indexes were calculated with the follow-
ing formula: HOMA  insulin (pico-
moles)/6.945  glucose (millimoles)/
22.5. Glucose and insulin excursions
during the OGTT were compared using
incrementalareasunderthecurve(AUCs)
at t  0 through t  120. Insulin sensi-
tivity was assessed using the composite
insulinsensitivityindexaccordingtoMat-
suda and Defronzo, calculated with the
following formula: 10,000/square root of
[fasting glucose  fasting insulin] 
[mean glucose  mean insulin during
OGTT] (12). For hyperglycemic clamps,
plasma insulin and C-peptide concentra-
tions were taken as measures of insulin
secretion, and glucagon levels was taken
as a measure of -cell function. First-
phase secretion measures during the hy-
perglycemic clamps were compared
between groups using incremental AUCs
at t  0 through t  10. The response to
argininewascomparedusingincremental
AUCs at t  120 through t  150. In
addition, pancreatic insulin secretion was
estimated using the C-peptide deconvo-
lutionmethoddescribedbyVanCauteret
al. (13).
Under stable conditions of constant
hyperglycemia, the amount of glucose in-
fused (milligrams per kilogram) equals
the amount of metabolized glucose (M).
M was calculated as the average glucose
infusion rate during the last 30 min of the
clamp (t  90 through t  120). The M
value divided by the average plasma insu-
lin concentration (I) during the same
interval, the M/I ratio, provides a mea-
surement of tissue sensitivity to insulin
ABCA1 and -cell function
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picomole per liter) (14).
The disposition index, calculated as
the product of the M/I ratio and the ﬁrst-
phase insulin response (incremental AUC
ofinsulinlevelsatt0throught10)is
a measure of the normal -cell response
adequate for any degree of insulin resis-
tance (14,15).
Statistical analyses
Results are reported as means  SD or as
medians (interquartile range [IQR]) un-
less noted otherwise. All incremental
AUCs were calculated using the trapezoi-
dal rule. Differences in continuous base-
line variables between carriers and
control subjects were tested using Stu-
dent’s t test, except for triglycerides,
which are known to be nonnormally dis-
tributed. Differences in triglycerides and
continuous outcome variables between
carriers and control subjects were tested
using the nonparametric Mann-Whitney
U test. In addition, where appropriate, P
values for interaction between time and
genotype were calculated using two-way
repeated-measures ANOVA. Differences
incategoricalvariablesweretestedusinga
Pearson 	
2 test. P 
 0.05 was taken to
indicate signiﬁcant differences. All statis-
tical analyses were performed with SPSS
software (SPSS, Chicago, IL).
RESULTS— We performed OGTTs in
15 subjects heterozygous for validated
loss-of-function mutations in ABCA1 and
14 control subjects. Carriers were re-
cruited from ﬁve different families (four
C1477R carriers, three M1091T carriers,
three R587W carriers, four L996P carri-
ers, and one Q978X carrier); family con-
trol subjects were siblings, cousins, or
partners of a carrier. Baseline characteris-
tics are shown in Table 1. Carriers had
50% reduced HDL cholesterol levels
compared with control subjects, but, im-
portantly, LDL cholesterol levels were
comparable between carriers and noncar-
riers. Fasting glucose levels were not sig-
niﬁcantly different between carriers and
control subjects. Glucose curves tended
to be different when assessed using a ge-
notype  time interaction (P  0.07).
However, the incremental area under the
glucose tolerance curve was signiﬁcantly
greaterforcarrierscomparedwithcontrol
subjects (245 [IQR 153–353] vs. 155
mmol   l
1   min
1 [84–198], P 
 0.05)
(Fig. 1A). Insulin curves were not signiﬁ-
cantly different between groups (incre-
mental AUC [18.5–46.2] vs. 32.1 nmol  
l
1   min
1 [18.3–48.6], P  0.93; geno-
type  time interaction P  0.31) (Fig.
1B).Compositeinsulinsensitivityindexes
also did not differ between groups (carri-
ers6.6[3.1–7.9]vs.noncarriers6.0[4.3–
9.4], P  0.69). These data suggest that
carriers of ABCA1 mutations have mildly
reduced glucose tolerance, which is not
explained by increased insulin resistance.
A subgroup of 16 subjects who par-
ticipated in the OGTT also agreed to par-
ticipate in a hyperglycemic clamp to
evaluate -cell function. This group con-
sisted of four C1477R carriers, two
M1091T carriers, one L996P carrier, one
Q978Xcarrier,andeightcontrolsubjects.
Baseline characteristics are listed supple-
mentary Table A (available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-1562/DC1). Plasma
glucose levels were ﬁxed at 13 mmol/l by
titrating the glucose infusion rate (Fig.
2A). Glucose infusion rates (M) tended to
be lower in carriers (8.1 [IQR 6.0–12.0]
vs. 12.4 mg   kg
1   min
1 [IQR 10.8–
19.1], P  0.059) (Fig. 2B), probably
reﬂecting reduced glucose tolerance. In-
cremental glucagon AUCs were compara-
ble between groups (ﬁrst phase 39
[98 to 11] vs. 82 pmol   l
1   min
1
[137to69],P0.16;responsetoar-
ginine 423 [161–515] vs. 331 pmol   l
1  
min
1 [299–350], P  0.25; P values for
genotype  time interactions were 0.09
and 0.99, respectively) (Fig. 2C). First-
phaseinsulinresponsetoanacuteglucose
bolus, measured by incremental AUC,
tendedtobelowerincarriersthanincon-
trol subjects (0.79 [0.42–1.58] vs. 1.53
nmol l
1 min
1[1.06–3.71],P0.09)
butwassigniﬁcantlylowerwhenassessed
using genotype  time interaction (P 

0.001) (Fig. 2D). Incremental AUCs
of the ﬁrst-phase C-peptide response
were markedly lower in carriers versus
control subjects (3.50 [1.09–5.02] vs.
6.62 nmol   l
1   min
1 [4.73–11.48],
P 
 0.01; genotype  time interaction
P 
 0.01) (Fig. 2E). First-phase insulin
secretionratesestimatedbyC-peptidede-
convolution were lower in carriers as
well (2.45 [1.88–3.42] vs. 3.81 nmol/m
2
[2.92–6.95], P 
 0.05; genotype  time
interaction P 
 0.005) (Fig. 2F). To-
gether, these data indicate reduced ﬁrst-
phase insulin secretion in response to
glucose.
Incontrast,theinsulinandC-peptide
response to arginine stimulation did not
differ signiﬁcantly between carriers and
noncarriers (insulin incremental AUC
17.3 [IQR 9.0–21.9] vs. 16.3 nmol   l
1  
min
1 [14.1–22.2], P  0.75; geno-
type  time interaction P  0.98 and
C-peptide incremental AUC 26.1 [20.5–
40.5] vs. 34.6 nmol   l
1   min
1 [23.4–
50.3], P  0.40; genotype  time
interaction P  0.40, respectively) (Fig.
Table 1—Baseline characteristics of participants in the OGTT
Noncarriers Carriers P
n 14 15
Age (years) 52  95 5  13 0.51
Men 7 (50) 9 (60) 0.59
BMI 24.9  2.9 24.7  2.8 0.89
Cholesterol (mmol/l)
Total 4.99  1.20 4.50  0.92 0.23
LDL 3.09  0.97 3.22  0.83 0.71
HDL 1.57  0.40 0.70  0.30 
0.001
Triglycerides (mmol/l) 0.68 0.44–0.92 0.75 0.53–2.14 0.17
Fasting glucose (mmol/l) 5.2  0.5 5.1  1.2 0.76
Fasting insulin (pmol/l) 43  20 48  35 0.62
HOMA index 1.44  0.71 1.65  1.30 0.60
History of CAD 0 (0) 3 (20) 0.08
History of diabetes 0 (0) 0 (0) N/A
Family history of diabetes 1 (7) 0 (0) 0.29
Smokers 2 (14) 2 (13) 0.94
Medication use
Statins 1 (7) 5 (33) 0.08
Hormone replacement therapy 1 (7) 0 (0) 0.29
Thiazides 0 (0) 0 (0) N/A
-Blockers 1 (7) 1 (7) 0.96
Data are means  SD, n (%), or median IQR.
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sponse to arginine were also similar be-
tween groups (13.4 [8.70–17.1] vs. 14.1
nmol/m
2 [7.39–16.5], P  0.92; geno-
type  time interaction P  0.36) (Fig.
2I).
Toexcludeinsulinresistanceasapos-
sible cause for the difference in glucose
tolerance, we calculated the M/I ratio as a
measure of insulin sensitivity (14) and
found that it was comparable between
groups (22 g   kg
1   min
1 per pmol/l
[IQR 19–33] for carriers and 22 g  
kg
1   min
1 per pmol/l [IQR 17–41] for
noncarriers;P0.96),indicatingthatin-
sulinsensitivityisnotalteredincarriersof
loss-of-function ABCA1 mutations, con-
sistent with data from mice lacking Abca1
(5). In contrast, the disposition index, an
index for -cell function adjusted for in-
sulin sensitivity (15), was signiﬁcantly
lower in carriers than in control subjects
(407 [225–789] for carriers and 1,605
[976–2,295] for noncarriers; P 
 0.02).
CONCLUSIONS — Here we show
that the cholesterol transporter ABCA1
inﬂuences -cell function in humans.
Heterozygous carriers of ABCA1 muta-
tions displayed mild hyperglycemia with
no difference in insulin response after an
oral glucose challenge compared with
noncarriers of similar age, sex, and BMI.
Using hyperglycemic clamps, we found
that ABCA1 heterozygotes show a re-
duced ﬁrst-phase insulin response to hy-
perglycemia and normal insulin
sensitivity, resulting in a markedly de-
creased disposition index. Glucagon lev-
els were similar throughout the study,
suggesting that the observations were not
affected by a difference in glucose dispo-
sition. Collectively, these ﬁndings point
to a defect in -cell function in ABCA1
heterozygotes.
Mice with targeted deletion of Abca1
in-cellsaccumulatecholesterolinislets,
leadingtoimpairedinsulinsecretionboth
in vivo and in vitro (5). Our data extend
these ﬁndings and suggest that choles-
terol handling may also be a determinant
of-cellfunctioninhumans.Thespeciﬁc
means by which ABCA1 dysfunction im-
pairs-cellfunctionremainincompletely
understood. Glucose enters the -cell via
aGLUT,whereuponitismodiﬁedbyglu-
cokinase in the rate-limiting step in glu-
cose sensing. The subsequent glucose
metabolism pathway results in closing of
the ATP-sensitive potassium channel,
membrane depolarization, calcium inﬂux
into the cell via the L-type calcium chan-
nel, and exocytosis of insulin-containing
granules (16). This ﬁrst-phase secretory
response is augmented by a potassium
channel-independent pathway, which is
largely responsible for the second-phase
insulin response (17). Arginine is known
to stimulate insulin secretion by directly
inducing membrane depolarization inde-
pendent of potassium channels and thus
largely independent of glucose sensing
and glucose metabolism pathways
(18–21).
In ABCA1 heterozygotes, the ﬁrst-
phase insulin response was signiﬁcantly
impaired, whereas insulin secretion dur-
ingsteadyhyperglycemia(betweent90
andt120)wasnotstatisticallydifferent
between groups. The secretory response
to arginine was also comparable between
carriers and noncarriers. These data sug-
gest that ABCA1 dysfunction does not
limit insulin secretion per se but rather
the insulin release in response to an acute
glucose challenge. In light of these obser-
vations,itseemsunlikelythatisletcholes-
terol accumulation due to -cell ABCA1
dysfunction results in a substantial loss of
-cell mass. This ﬁnding is consistent
with the observation that mice with a de-
letion of -cell Abca1 have normal -cell
mass (5).
Ourobservationsarebestexplainedif
ABCA1 dysfunction has a predominant
impact on ﬁrst-phase GSIS by affecting
pathways upstream of -cell membrane
depolarization. In support of this notion,
cholesteroldepletionofHIT-T15hamster
insulinoma cells using methyl--
cyclodextrin results in redistribution of
voltage-gated potassium channels and a
marked enhancement of GSIS (22). Sim-
ilarly, the treatment of islets with methyl-
-cyclodextrin or mevastatin increases
GSIS,whereascholesteroloverloadingre-
duces GSIS (23). In the latter study, these
effects were found to be related to intra-
cellular glucose metabolism: a cholester-
ol-enriched lipid environment of insulin
granules reduced cytoplasmic glucoki-
nase activity indirectly by trapping glu-
cokinase in insulin granules (23). ABCA1
heterozygotes may therefore display im-
paired ﬁrst-phase GSIS because of excess
islet cholesterol interfering with glucose
sensing and downstream -cell mem-
brane depolarization.
Our data suggest that the cholesterol
accumulation observed in -cells of mice
with -cell-speciﬁc Abca1 deletion may
also occur in humans with heterozygous
mutations. However, the normal secre-
tory response to arginine in ABCA1 het-
erozygotes contrasts with the impaired
secretoryresponsetoarginineobservedin
mice with a total deﬁciency of -cell
Abca1 (5). This apparent discrepancy
may be due to a milder ABCA1 dysfunc-
Figure1—OGTTresultsincarriers(‚)versuscontrols(F).Plasmaglucoseandinsulincurvesafter75gorallyingestedglucose.A:Glucosecurves
were higher for carriers than for control subjects. B: Insulin curves were not different between groups. Error bars depict SEM.
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the knockout mice, which could be over-
come by the powerful secretagogue effect
of arginine. In our study, none of the
ABCA1 mutation carriers had diabetes,
possibly indicating that carriership is a
relatively mild islet susceptibility factor
for diabetes by itself. In addition, the rel-
atively small sample size of the present
study, which is related to the extreme
scarcity of subjects with loss-of-function
mutations in ABCA1, should be consid-
ered as a limitation. At this point, insufﬁ-
cient data are available to make a broad
statement regarding their risk of diabetes.
An inherent limitation to all case-control
studies is that matched groups may differ
in respects other than just the trait of in-
terest. We controlled for BMI, age, and
sex, and none of the participants had di-
abetes. Therefore, we believe we have at
least minimized the chance that the ab-
normalities in glucose homeostasis were
due to anything else but the ABCA1 mu-
tation status.
A recent study reported that four ho-
mozygous patients with Tangier disease
had signiﬁcantly greater excursion of
OGTT curves after a 75-g glucose load
comparedwithunrelatedcontrolsubjects
(24) in agreement with our ﬁndings in
ABCA1 heterozygotes. These authors did
not report additional studies of -cell
function. However, all four subjects in
this study had preexisting type 2 diabetes
(fasting glucose values 9.05–10.0 mmol/
l),suggestingthatthesepatientsmayhave
been subject to selection bias. It will be
necessary to determine the true preva-
lence of type 2 diabetes in patients with
Tangier disease to determine whether
they are indeed at increased risk for de-
veloping type 2 diabetes.
In summary, we show that ABCA1 is
important for normal -cell function in
humans. our understanding of the role of
ABCA1 in -cell function and glucose
homeostasis.
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Figure2—Hyperglycemicclampresultsincarriers(‚)versuscontrols(F).A:Plasmaglucosecurvesduringthehyperglycemicclampweresimilar
between carriers and noncarriers. B: The glucose infusion rate (GIR) under steady-state conditions, an approximation of the amount of glucose
metabolized(M),tendedtobelowerincarriers,reﬂectingreducedglucosetolerance(P0.06)C:Glucagoncurves,asameasureof-cellfunction,
did not differ between carriers and noncarriers during the clamp. D, E, and F: The ﬁrst-phase insulin and C-peptide responses to an acute glucose
bolus,aswellasinsulinsecretionrates(ISR)duringthisperiod,werelowerincarriersthanincontrolsubjects.G,H,andI:Therewerenosigniﬁcant
differences in these measures between carriers and noncarriers in response to arginine. Error bars depict SEM.
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